From CNBC · Annika Kim Constantino · · 1m 20s
Moderna raises 2026 outlook on strong vaccine momentum
Moderna beat earnings estimates and raised full-year guidance as newer vaccines gain traction in international markets.
In brief
Moderna beat earnings estimates and raised full-year guidance as newer vaccines gain traction in international markets. Moderna beat third-quarter estimates and raised 2026 revenue growth guidance to fifteen to twenty-five percent from up to ten percent, citing new product launches and geographic diversification…
Moderna beats estimates, raises outlook
Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth as newer products gain momentum.
New guidance: fifteen to twenty-five percent growth
The biotech company now expects two thousand twenty-six revenue growth of fifteen percent to twenty-five percent, up from its previous guidance of up to ten percent.
CEO credits new products and geography
Moderna CEO Stéphane Bancel said new product launches and the diversification of geography drove the strong third quarter performance.
“The new product and the diversification of geography is what has led to such a strong Q3”
Q3 results beat Wall Street expectations
Moderna reported earnings per share of thirty-eight cents versus an expected loss of one dollar twenty-five, and revenue of one point three one billion dollars versus eight hundred eighty-five point one million dollars expected.
New vaccines drive international revenue growth
Third-quarter revenue jumped twenty-nine percent to one point three one billion dollars, boosted by higher Covid vaccine sales in international markets and long-term government partnerships.
In short
Moderna beat third-quarter estimates and raised 2026 revenue growth guidance to fifteen to twenty-five percent from up to ten percent, citing new product launches and geographic diversification.
